Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management

Area of Science:

• Oncology
• Dermatology
• Genomics

Background:

• Cutaneous squamous cell carcinoma (CSCC) poses a metastatic risk, especially in high-risk patients.
• Gene expression profile (GEP) testing is a new tool for assessing this risk.

Purpose of the Study:

• To establish a framework for integrating GEP testing into clinical practice for CSCC management.
• To guide healthcare providers in utilizing patient-specific tumor biology for treatment decisions.

Main Methods:

• An expert panel convened to identify clinical decision points for GEP testing in CSCC.
• Focus areas included nodal evaluation, adjuvant radiation therapy, and follow-up strategies.
• The framework is intended for use until prospective trial data is definitive.

Main Results:

• GEP testing can inform decisions regarding nodal evaluation in high-risk CSCC.
• The results can aid in determining the need for adjuvant radiation therapy.
• GEP testing provides an additional data point for surveillance and follow-up planning.

Conclusions:

• GEP testing should supplement, not replace, standard of care for high-risk CSCC.
• Individualized management plans benefit from incorporating GEP prognostic data.
• Multidisciplinary input is crucial for optimal CSCC patient management decisions.